| Autor: |
Goldberg, Michael R., Lo, Man-Wai, Christ, David D., Chiou, Rita, Furtek, Christine I., Amit, Ohad, Carides, Alexandra, Biollaz, Jerome, Piguet, Valerie, Nussberger, Juerg, Brunner, Hans R. |
| Zdroj: |
Clinical Pharmacology & Therapeutics; January 1997, Vol. 61 Issue: 1 p59-69, 11p |
| Abstrakt: |
We investigated the tolerability and angiotensin II antagonist activity of oral DuP 532 in healthy male subjects. DuP 532 (1 to 200 mg) was well tolerated, with no effect on blood pressure or heart rate. Compared with losartan (100 mg), DuP 532 (200 mg) was a weak antagonist of pressor responses to intravenous angiotensin II. Maximum inhibition of diastolic pressor response was 86% (95% confidence interval [CI], 84%, 88%) approximately 4.6 hours after losartan and 48% (95% CI, 38%, 56%) 8.7 hours after DuP 532. Twenty-four hours after dosing, inhibition by losartan and DuP 532 was similar (40% to 45%). DUP 532 is extensively bound in human plasma, with an in vitro free fraction of 0.06. Although DuP 532 and EXP3174 (losartan's active metabolite) have similar AT1-receptor potency, and plasma concentrations of DuP 532 were much greater than losartan/EXP3174, the level of antagonism was much less for DuP 532. These results indicate that multiple factors determine the in vivo potency of angiotensin II antagonists, including affinity for and distribution to the receptor as modulated by plasma binding. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Plný text